MetFID: artificial neural network-based compound fingerprint prediction for metabolite annotation.

INTRODUCTION: Metabolite annotation is a critical and challenging step in mass spectrometry-based metabolomic profiling. In a typical untargeted MS/MS-based metabolomic study, experimental MS/MS spectra are matched against those in spectral libraries for metabolite annotation. Yet, existing spectral libraries comprise merely a marginal percentage of known compounds. OBJECTIVE: The objective is to develop a method that helps rank putative metabolite IDs for analytes whose reference MS/MS spectra are not present in spectral libraries. METHODS: We introduce MetFID, which uses an artificial neural network (ANN) trained for predicting molecular fingerprints based on experimental MS/MS data. To narrow the search space, MetFID retrieves candidates from metabolite databases using molecular formula or m/z value of the precursor ions of the analytes. The candidate whose fingerprint is most analogous to the predicted fingerprint is used for metabolite annotation. A comprehensive evaluation was performed by training MetFID using MS/MS spectra from the MoNA repository and NIST library and by testing with structure-disjoint MS/MS spectra from the NIST library, the CASMI 2016 dataset, and in-house MS/MS data from a cancer biomarker discovery study. RESULTS: We observed that training separate models for distinct ranges of collision energies enhanced model performance compared to a single model that covers a wide range of collision energies. Using MetaboQuest to retrieve candidates, MetFID prioritized the correct putative ID in the first place rank for about 50% of the testing cases. Through the independent testing dataset, we demonstrated that MetFID has the potential to improve the accuracy of ranking putative metabolite IDs by more than 5% compared to other tools such as ChemDistiller, CSI:FingerID, and MetFrag. CONCLUSION: MetFID offers a promising opportunity to enhance the accuracy of metabolite annotation by using ANN for molecular fingerprint prediction.

Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC) causes more than half a million annual deaths worldwide. Understanding the mechanisms contributing to HCC development is highly desirable for improved surveillance, diagnosis, and treatment. Liver tissue metabolomics has the potential to reflect the physiological changes behind HCC development. Also, it allows identification of biomarker candidates for future evaluation in biofluids and investigation of racial disparities in HCC. Tumor and nontumor tissues from 40 patients were analyzed by both gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) platforms to increase the metabolome coverage. The levels of the metabolites extracted from solid liver tissue of the HCC area and adjacent non-HCC area were compared. Among the analytes detected by GC-MS and LC-MS with significant alterations, 18 were selected based on biological relevance and confirmed metabolite identification. These metabolites belong to TCA cycle, glycolysis, purines, and lipid metabolism and have been previously reported in liver metabolomic studies where high correlation with HCC progression is implied. We demonstrated that metabolites related to HCC pathogenesis can be identified through liver tissue metabolomic analysis. Additionally, this study has enabled us to identify race-specific metabolites associated with HCC.